US 11963958
RET inhibitor for use in treating cancer having a RET alteration
granted A61KA61K31/506A61K45/06
Quick answer
US patent 11963958 (RET inhibitor for use in treating cancer having a RET alteration) held by Rigel Pharmaceuticals, Inc. expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 24
- CPC classes
- A61K, A61K31/506, A61K45/06, A61K9/0053, A61P